Name: | Ergotamine |
---|---|
PubChem Compound ID: | 115248 |
Description: | A vasoconstrictor found in ergot of Central Europe. It is a serotonin agonist that has been used as an oxytocic agent and in the treatment of MIGRAINE DISORDERS. |
Molecular formula: | C33H35N5O5 |
Molecular weight: | 581.662 g/mol |
Synonyms: |
Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha,8alpha)-; Ergotaminine; Isoergotamine; 639-81-6
|
Name: | Ergotamine |
---|---|
Name (isomeric): | DB00696 |
Drug Type: | small molecule |
Description: | A vasoconstrictor found in ergot of Central Europe. It is a serotonin agonist that has been used as an oxytocic agent and in the treatment of MIGRAINE DISORDERS. |
Brand: | Ergomar, Ergoton-A, Medihaler Ergotamine, Ergostat, Wigrettes, Ergotamin |
Brand name mixture: | Wigraine Suppositories(Belladonna + Caffeine + Ergotamine Tartrate), Gravergol Capsules(Caffeine + Dimenhydrinate + Ergotamine Tartrate), Cafergot Tab(Caffeine + Ergotamine Tartrate), Cafergot Pb Tab(Belladonna + Caffeine + Ergotamine (Ergotamine Tartrate) + Pentobarbital Sodium), Cafergot Sup(Caffeine + Ergotamine Tartrate), Cafergot Pb Sup(Bel... show more » |
Category: | Sympatholytics, Adrenergic alpha-Agonists, Analgesics, Non-Narcotic, Vasoconstrictor Agents |
CAS number: | 113-15-5 |
Indication: | For use as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so called "histaminic cephalalgia". |
---|---|
Pharmacology: |
Ergotamine is a vasoconstrictor and alpha adrenoreceptor antagonist. The pharmacological properties of ergotamine are extremely complex; some of its actions are unrelated to each other, and even mutually antagonistic. The drug has partial agonist and/or antagonist activity against tryptaminergic, dopaminergic and alpha adrenergic receptors dependin...
show more » |
Mechanism of Action: |
Ergotamine acts on migraine by one of two proposed mechanisms: 1) activation of 5-HT1D receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache, and 2) activation of 5-HT1D receptors on sensory nerve endings ...
show more » |
Absorption: | The bioavailability of sublingually administered ergotamine has not been determined. |
Biotransformation: | Hepatic. Ergotamine is metabolized by the liver by largely undefined pathways, and 90% of the metabolites are excreted in the bile. |
Half Life: | 2 hours |
Toxicity: | Signs of overexposure include irritation, nausea, vomiting, headache, diarrhea, thirst, coldness of skin, pruritus, weak pulse, numbness, tingling of extremities, and confusion. |
Affected organisms: | Humans and other mammals |
Food interaction: |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Drug interaction: |
|